Literature DB >> 22001307

A capture-recapture analysis demonstrated that randomized controlled trials evaluating the impact of diagnostic tests on patient outcomes are rare.

Lavinia Ferrante di Ruffano1, Clare Davenport, Anne Eisinga, Chris Hyde, Jonathan J Deeks.   

Abstract

OBJECTIVE: To estimate the number of randomized controlled trials (RCTs) published annually that evaluate the impact of diagnostic tests on patient outcomes to gauge the extent of available randomized evidence assessing the effectiveness of diagnostic tests. STUDY DESIGN AND
SETTING: Relevant RCTs published in 2004-2007 were identified from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL). Two search strategies were developed, one using diagnostic methodological terms and one using test names. Potentially relevant RCTs were identified by screening titles and abstracts. Final inclusion decisions were based on full-text review. A random 10% sample of all citations was independently screened by a second reviewer. Capture-recapture methodology was used to estimate the number of relevant RCTs missed by both searches.
RESULTS: One hundred thirty-five relevant RCTs were identified from the 23,888 records retrieved. Interobserver agreement was substantial. Capture-recapture methodology estimated that 148 (95% confidence interval: 140, 160) relevant RCTs were published in the 4-year period, an average of only 37 publications per year.
CONCLUSION: RCTs of diagnostic tests that evaluate patient outcomes are rare. Consequently recommendations on the use of diagnostic tests can rarely be made on the basis of randomized comparisons, lower grade evidence frequently being the best available.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22001307     DOI: 10.1016/j.jclinepi.2011.07.003

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  16 in total

1.  Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.

Authors:  Oke Gerke; Mads H Poulsen; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

2.  Interim analyses in diagnostic versus treatment studies: differences and similarities.

Authors:  Oke Gerke; Poul Flemming Høilund-Carlsen; Mads Hvid Poulsen; Werner Vach
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

3.  Demonstrating the benefits of clinical nuclear imaging: is it time to add economic analysis?

Authors:  Poul F Høilund-Carlsen; Oke Gerke; Werner Vach
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09       Impact factor: 9.236

Review 4.  Methodologic approaches to evaluating new highly sensitive diagnostic tests: avoiding overdiagnosis.

Authors:  Joris A H de Groot; Christiana A Naaktgeboren; Johannes B Reitsma; Karel G M Moons
Journal:  CMAJ       Date:  2016-07-04       Impact factor: 8.262

Review 5.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

6.  Do clinical practice guidelines consider evidence about diagnostic test consequences on patient-relevant outcomes? A critical document analysis.

Authors:  Mariska K Tuut; Jako S Burgers; Trudy van der Weijden; Miranda W Langendam
Journal:  J Eval Clin Pract       Date:  2021-09-23       Impact factor: 2.336

7.  Prenatal genetic testing for cystic fibrosis: a systematic review of clinical effectiveness and an ethics review.

Authors:  Sharon J M Kessels; Drew Carter; Benjamin Ellery; Skye Newton; Tracy L Merlin
Journal:  Genet Med       Date:  2019-08-30       Impact factor: 8.822

8.  From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling study.

Authors:  Hendrik Koffijberg; Bas van Zaane; Karel G M Moons
Journal:  BMC Med Res Methodol       Date:  2013-01-31       Impact factor: 4.615

9.  How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?

Authors:  Ala Szczepura; Susan Manzoor; Katherine Hardy; Nigel Stallard; Helen Parsons; Savita Gossain; Peter M Hawkey
Journal:  BMC Infect Dis       Date:  2014-03-21       Impact factor: 3.090

10.  Evidence used in model-based economic evaluations for evaluating pharmacogenetic and pharmacogenomic tests: a systematic review protocol.

Authors:  Jaime L Peters; Chris Cooper; James Buchanan
Journal:  BMJ Open       Date:  2015-11-11       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.